Author: Revial Labs

Across 23–24 July 2026 an FDA advisory committee recommended six peptides — BPC-157, KPV, TB-500, MOTS-C, Epitalon and Semax — for the 503A compounding list, rejecting DSIP. What the vote means, and what it does not.

HGH and HGH Fragment 176-191 are easily confused but structurally distinct. A research-context guide to the difference between the full hormone and the tail fragment, plus what IU means and how it affects reconstitution.

Metabolic peptide research is moving from single and dual agonists toward triple agonists that engage three receptors at once. A research-context overview of the shift, from Tirzepatide to Retatrutide.

BPC-157 and TB-500 are the most commonly paired peptides in research discussion. A research-context look at their different origins, why their mechanisms are studied side by side, and the limits of the evidence.

A plain-English, research-context explainer of the 2026 FDA peptide reclassification: what came off Category 2 in April, what it does and does not mean, and what the July PCAC review decides next.

A practical comparison of the two standard peptide reconstitution solvents — when to use bacteriostatic water, when to switch to acetic acid water, and why.

What a Certificate of Analysis is, the key purity and identity tests (HPLC and mass spectrometry), and why independent third-party testing is the standard serious researchers rely on.

A clear, step-by-step guide to reconstituting lyophilised research peptides — solvents, concentration, technique and storage for laboratory settings.